Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 36,100 shares, a decline of 23.2% from the February 13th total of 47,000 shares. Based on an average daily trading volume, of 830,300 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.1% of the shares of the company are short sold.

Biodexa Pharmaceuticals Stock Up 11.6 %

NASDAQ BDRX opened at $2.12 on Tuesday. Biodexa Pharmaceuticals has a 52 week low of $1.84 and a 52 week high of $74.00. The company’s 50-day simple moving average is $3.86.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.